drugset / Trial / NCT01568034

A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

NCT01568034

Phase 2 Completed 10 enrolled Bial - Portela C S.A.
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to investigate the effect of BIA 9-1067 on the levodopa pharmacokinetics when administered in combination with immediate release levodopa/carbidopa or levodopa/benserazide in Parkinson's Disease (PD) patients.

Timeline

Start
2009-04
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Opicapone Small molecule 25 mg
Subject Opicapone Small molecule 50 mg
Subject Opicapone Small molecule 100 mg
Background Benzerazide Unknown 25 mg
Background Carbidopa Unknown 25 mg
Background Levodopa Small molecule 100 mg

Indications